A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic-Reference-Cited by-同舟云学术

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic

Published:2020-11-08 Issue:3 Volume:35 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Hansel K.¹^ORCID,Zangrilli A.²,Bianchi L.²,Peris K.³^ORCID,Chiricozzi A.³^ORCID,Offidani A.⁴,Diotallevi F.⁴^ORCID,Fargnoli M.C.⁵^ORCID,Esposito M.⁵^ORCID,Amerio P.⁶,Gualdi G.⁶^ORCID,Bianchi L.¹,Stingeni L.¹^ORCID

Affiliation:

1. Dermatology Section Department of Medicine University of Perugia Perugia Italy

2. Dermatology Unit Policlinico Tor Vergata Department of Systems Medicine University of Rome Tor Vergata Rome Italy

3. Dermatologia Dipartimento Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

4. Dermatological Clinic Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy

5. Dermatology Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy

6. Department of Medicine and Aging Science Dermatologic Clinic, G. D'Annunzio University Chieti Italy

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.17003

Reference7 articles.

1. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

2. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

3. Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data of a real‐life 16‐week retrospective study

4. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals

5. Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis;JAMA Dermatology;2024-08-01

2. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study;Actas Dermo-Sifiliográficas;2024-03

3. Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis;Experimental Dermatology;2024-01

4. Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review;Annals of Dermatology;2024

5. One Dose Risankizumab Effectiveness in Psoriasis: A Real‐Life Multicentre Study;Dermatologic Therapy;2024-01